Allergan Inc (NYSE:AGN): Institutional Investors Aren’t Crazy About It

Allergan plc (NYSE:AGN) Logo

Sentiment for Allergan Inc (NYSE:AGN)

Allergan Inc (NYSE:AGN) institutional sentiment decreased to 0 in 2019 Q2. Its down -2.00, from 2 in 2019Q1. The ratio dived, as 0 investment professionals increased and started new equity positions, while 4 reduced and sold equity positions in Allergan Inc. The investment professionals in our partner’s database now possess: 20,340 shares, down from 25,607 shares in 2019Q1. Also, the number of investment professionals holding Allergan Inc in their top 10 equity positions was flat from 0 to 0 for the same number . Sold All: 1 Reduced: 3 Increased: 0 New Position: 0.

Allergan plc, a specialty pharmaceutical company, develops, makes, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. The company has market cap of $54.50 billion. It operates through US Specialized Therapeutics, US General Medicine, and International divisions. It currently has negative earnings. The firm offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, womenÂ’s health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as AlzheimerÂ’s disease.

The stock decreased 0.13% or $0.21 during the last trading session, reaching $166.14. About 2.12M shares traded. Allergan plc (NYSE:AGN) has declined 12.77% since September 13, 2018 and is downtrending. It has underperformed by 12.77% the S&P500.

Analysts await Allergan plc (NYSE:AGN) to report earnings on October, 29. They expect $4.21 EPS, down 0.94 % or $0.04 from last year’s $4.25 per share. AGN’s profit will be $1.38 billion for 9.87 P/E if the $4.21 EPS becomes a reality. After $4.38 actual EPS reported by Allergan plc for the previous quarter, Wall Street now forecasts -3.88 % negative EPS growth.

Mitchell Mcleod Pugh & Williams Inc holds 0.46% of its portfolio in Allergan plc for 3,982 shares. Callahan Advisors Llc owns 12,774 shares or 0.38% of their US portfolio. Moreover, Cullinan Associates Inc has 0.02% invested in the company for 2,000 shares. The Pennsylvania-based Staley Capital Advisers Inc has invested 0.02% in the stock. Gemmer Asset Management Llc, a California-based fund reported 145 shares.

Allergan plc (NYSE:AGN) Ratings Coverage

Ratings analysis reveals 40% of Allergan’s analysts are positive. Out of 10 Wall Street analysts rating Allergan, 4 give it “Buy”, 0 “Sell” rating, while 6 recommend “Hold”. The lowest target is $13300 while the high is $18900. The stock’s average target of $166.50 is 0.22% above today’s ($166.14) share price. AGN was included in 25 notes of analysts from March 20, 2019. The rating was maintained by UBS with “Buy” on Wednesday, April 3. UBS maintained Allergan plc (NYSE:AGN) on Thursday, May 9 with “Buy” rating. On Thursday, September 12 the stock rating was maintained by UBS with “Buy”. As per Thursday, May 9, the company rating was maintained by Raymond James. The firm has “Outperform” rating given on Wednesday, May 8 by Wells Fargo. The rating was maintained by Credit Suisse on Monday, March 25 with “Hold”. The firm earned “Market Perform” rating on Thursday, July 18 by Leerink Swann. On Monday, March 25 the stock rating was maintained by Stifel Nicolaus with “Hold”. The rating was maintained by RBC Capital Markets with “Hold” on Monday, March 25. Piper Jaffray maintained the shares of AGN in report on Wednesday, March 20 with “Hold” rating.

More notable recent Allergan plc (NYSE:AGN) news were published by: which released: “Allergan and Molecular Partners Announce Acceptance of US FDA Biologics License Application and Validation of EMA Marketing Authorisation for Abicipar pegol in Patients with Neovascular (Wet) Age-related Macular Degeneration – PRNewswire” on September 09, 2019, also with their article: “How Will Johnson & Johnson’s Opioid Case Ruling Impact Big Pharma Stocks? – The Motley Fool” published on September 05, 2019, published: “Should You Buy AbbVie for the Dividend? – Motley Fool” on August 27, 2019. More interesting news about Allergan plc (NYSE:AGN) were released by: and their article: “Amgen And Allergan Announce Positive Top-Line Results From Comparative Clinical Study Of ABP 798, Biosimilar Candidate To Rituxan® (Rituximab) – PRNewswire” published on August 22, 2019 as well as‘s news article titled: “Is Allergan plc (AGN) A Good Stock To Buy ? – Yahoo Finance” with publication date: June 10, 2019.

Allergan plc (NYSE:AGN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.